Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 52, Issue 5, 2013, Pages 482-492

  Hilton, Robert C ^a   Rengasamy, Manivel ^b   Mansoor, Brandon ^c   He, Jiayan ^d   Mayes, Taryn ^e   Emslie, Graham J ^e   Porta, Giovanna ^f   Clarke, Greg N ^g   Wagner, Karen Dineen ^f   Birmaher, Boris ^f   Keller, Martin B ^h   Ryan, Neal ^f   Shamseddeen, Wael ⁱ   Asarnow, Joan Rosenbaum ^j   Brent, David A ^f  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

antidepressants; cognitive behavioral therapy (CBT); comorbidity; secondary outcomes; Treatment of Resistant Depression in Adolescents (TORDIA)

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; BEHAVIOR DISORDER; CLINICAL ASSESSMENT; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DRUG DOSE INCREASE; DRUG EFFICACY; DYSTHYMIA; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SELF REPORT; SYMPTOM;

ADOLESCENT; ANXIETY; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; BEHAVIORAL SYMPTOMS; CITALOPRAM; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COMORBIDITY; CYCLOHEXANOLS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FLUOXETINE; HUMANS; PAROXETINE; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84876791765     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2013.02.013     Document Type: Article

References (47)

1. A. Angold, E.J. Costello, and A. Erkanli Comorbidity J Child Psychol Psychiatry 40 1999 57 87
2. H.R. Bird, M.S. Gould, and B.M. Staghezza Patterns of diagnostic comorbidity in a community sample of children aged 9 through 16 years J Am Acad Child Adolesc Psychiatry 32 1993 361 368
3. E.J. Costello, S. Mustillo, A. Erkanli, G. Keeler, and A. Angold Prevalence and development of psychiatric disorders in childhood and adolescence Arch Gen Psychiatry 60 2003 837 844
4. D.A. Brent, and V.R. Weersing Depressive disorders in childhood and adolescence M. Rutter, D. Bishop, D. Pine, Rutter's Child and Adolescent Psychiatry 5th ed. 2008 Blackwell Publishing Malden, MA 587 612
5. B. Vitiello, G. Emslie, and G. Clarke Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample J Clin Psychiatry 72 2011 388 396
6. A. Cheung, T. Mayes, and A. Levitt Anxiety as a predictor of treatment outcome in children and adolescents with depression J Child Adolesc Psychopharmacol 20 2010 211 216
7. W.B. Daviss A review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment J Child Adolesc Psychopharmacol 18 2008 565 571
8. D. Brent, G. Emslie, and G. Clarke Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial JAMA 299 2008 901 913
9. P.H. Silverstone, and A. Ravindran Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group J Clin Psychiatry 60 1999 22 28
10. R.A. Hansen, G. Gartlehner, K.N. Lohr, B.N. Gaynes, and T.S. Carey Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder Ann Intern Med 143 2005 415 426
11. A. Cipriani, T.A. Furukawa, and G. Salanti Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 373 2009 746 758
12. T.C. Baghai, P. Blier, and D.S. Baldwin General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry Eur Arch Psychiatry Clin Neurosci 261 Suppl 3 2011 207 245
13. G. Gartlehner, R.A. Hansen, and L.C. Morgan Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis Ann Intern Med 155 2011 772 785
14. J.A. Bridge, S. Iyengar, and C.B. Salary Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials JAMA 297 2007 1683 1696
15. O.A. Uthman, and J. Abdulmalik Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis Curr Med Res Opin 26 2010 53 59
16. J.T. Walkup, A.M. Albano, and J. Piacentini Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety N Engl J Med 359 2008 2753 2766
17. J.R. Asarnow, G. Emslie, and G. Clarke Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response J Am Acad Child Adolesc Psychiatry 48 2009 330 339
18. D.A. Brent, D.J. Kolko, and B. Birmaher Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression J Am Acad Child Adolesc Psychiatry 37 1998 906 914
19. B.D. Kennard, G.N. Clarke, and V.R. Weersing Effective components of TORDIA cognitive-behavioral therapy for adolescent depression: preliminary findings J Consult Clin Psychol 77 2009 1033 1041
20. P.M. Lewinsohn, P. Rohde, and J.R. Seeley Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications Clin Psychol Rev 18 1998 765 794
21. D. Ougrin Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis BMC Psychiatry 11 2011 200
22. I. Herrera-Guzman, J.E. Herrera-Abarca, and E. Gudayol-Ferre Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder Psychiatry Res 177 2010 323 329
23. A.R. Zarinara, M.R. Mohammadi, and N. Hazrati Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial Hum Psychopharmacol 25 2010 530 535
24. H. Quintana, G.J. Butterbaugh, W. Purnell, and A.K. Layman Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents Child Psychiatry Hum Dev 37 2007 241 253
25. R.L. Findling Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series J Child Adolesc Psychopharmacol 6 1996 165 175
26. G.D. Gammon, and T.E. Brown Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder J Child Adolesc Psychopharmacol 3 1993 1 10
27. H. Steiner, V. Van Waes, and M. Marinelli Fluoxetine potentiates methylphenidate-induced gene regulation in addiction-related brain regions: concerns for use of cognitive enhancers? Biol Psychiatry 67 2010 592 594
28. Antshel KM, Faraone SV, Gordon M. Cognitive behavioral treatment outcomes in adolescent ADHD [published online May 26, 2012]. J Atten Disord. http://dx.doi.org/10.1177/1087054712443155.
29. D.A. Brent, G.J. Emslie, and G.N. Clarke Predictors of spontaneous and systematically assessed suicidal adverse events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study Am J Psychiatry 166 2009 418 426
30. E.F. Coccaro, R.J. Lee, and R.J. Kavoussi A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder J Clin Psychiatry 70 2009 653 662
31. J. Puig-Antich Major depression and conduct disorder in prepuberty J Am Acad Child Psychiatry 21 1982 118 128
32. P. Rohde, G.N. Clarke, D.E. Mace, J.S. Jorgensen, and J.R. Seeley An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder J Am Acad Child Adolesc Psychiatry 43 2004 660 668
33. W. Guy ECDEU Assessment Manual for Psychopharmacology 2nd ed. 1976 US Government Printing Office Washington, DC
34. E.O. Poznanski, L.N. Freeman, and H.B. Mokros Children's Depression Rating Scale-Revised Psychopharmacol Bull 21 1985 979 989
35. J. Kaufman, B. Birmaher, and D. Brent Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data J Am Acad Child Adolesc Psychiatry 36 1997 980 988
36. B. Birmaher, S. Khetarpal, and D. Brent The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics J Am Acad Child Adolesc Psychiatry 36 1997 545 553
37. A.L. Robin, and S.L. Foster Negotiating Parent-Adolescent Conflict: a Behavioral Family Systems Approach 1989 Guilford Press New York
38. G.J. Emslie, T. Mayes, and G. Porta Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes Am J Psychiatry 167 2010 782 791
39. L. Kirisci, A. Mezzich, and R. Tarter Norms and sensitivity of the adolescent version of the Drug Use Screening Inventory Addict Behav 20 1995 149 157
40. D.J. Sakolsky, J.M. Perel, and G.J. Emslie Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study J Clin Psychopharmacol 31 2011 92 97
41. A.T. Beck, R.A. Steer, and M.G. Garbin Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation Clin Psychol Rev 8 1988 77 100
42. D. Shaffer, M.S. Gould, and J. Brasic A Children's Global Assessment Scale (CGAS) Arch Gen Psychiatry 40 1983 1228 1231
43. D. Axelson, B.J. Birmaher, and D. Brent A preliminary study of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children mania rating scale for children and adolescents J Child Adolesc Psychopharmacol 13 2003 463 470
44. W.M. Reynolds, and J.J. Mazza Assessment of suicidal ideation in inner-city children and young adolescents: reliability and validity of the Suicidal Ideation Questionnaire-JR School Psych Rev 28 1999 17 30
45. M. Rengasamy, B. Mansoor, R.C. Hilton, G. Porta, J. He, and G.J. Emslie The Bi-directional relationship between parent-child conflict and treatment outcome in treatment-resistant adolescent depression J Am Acad Child Adolesc Psychiatry 52 2013 370 377
46. M. Stone, T. Laughren, and M.L. Jones Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration BMJ 339 2009 b2880
47. J.R. Weisz, B.F. Chorpita, and L.A. Palinkas Testing standard and modular designs for psychotherapy treating depression, anxiety, and conduct problems in youth: a randomized effectiveness trial Arch Gen Psychiatry 69 2012 274 282